Metronidazolo Bioindustria Lim

Metronidazole, the active ingredient in Metronidazolo Bioindustria Lim, is a nitroimidazole presented as an injectable solution for intravenous use. It is employed to treat infections caused by susceptible anaerobic bacteria and certain protozoa, and is commonly prescribed for adult and pediatric patients requiring systemic therapy. The drug penetrates tissues and body fluids, achieving therapeutic concentrations in the bloodstream, peritoneal cavity, and central nervous system, which supports its use in a range of intra‑abdominal, gynecologic, and systemic infections. Its broad spectrum activity makes it a valuable option in hospital settings for managing mixed microbial populations.

GNH USA supplies Metronidazolo Bioindustria Lim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metronidazole is indicated for infections where anaerobic bacteria or susceptible protozoa are involved. It provides targeted antimicrobial activity across several disease categories.

- Anaerobic bacterial infections: eradicates susceptible anaerobes, reducing infection severity. - Bacterial vaginosis: restores normal vaginal flora by eliminating overgrowth of anaerobic bacteria. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms and preventing transmission. - Amoebiasis: destroys Entamoeba histolytica trophozoites, treating intestinal and extra‑intestinal disease. - Intra‑abdominal infections: provides systemic coverage of anaerobic organisms in peritonitis and abscesses.

Metronidazole may cause a range of adverse reactions, from mild to severe. Patients should be monitored for any new symptoms during therapy.

Common Side Effects: - Nausea - Metallic taste - Headache - Diarrhea

Serious or Rare Side Effects: - Seizures - Peripheral neuropathy - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for potential complications. - Renal impairment: adjust therapy based on renal function. - Hepatic disease: monitor liver enzymes during prolonged use. - Alcohol consumption: avoid alcohol due to a disulfiram‑like reaction. - Pregnancy: use only if benefits outweigh risks; safety not established. - Concomitant neurotoxic drugs: monitor for additive neurotoxicity. - Store at below 25°C: keep in original container, protect from moisture and light.

Metronidazole can interact with several medicines, altering efficacy or safety. Interactions are grouped by clinical significance.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: increased anticoagulant effect; monitor INR closely. - Lithium: may raise lithium levels, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole plasma concentrations. - Cimetidine: may increase metronidazole levels. - Cyclosporine: may elevate cyclosporine concentrations, requiring dose adjustment.